Non-invasive monitoring for heart transplant patients
Part of Heart & circulation clinical trials.
This study tests a new way to monitor heart transplant patients for rejection using blood tests and other non-invasive tools, which might reduce the need for invasive biopsies. If you've had a recent heart transplant and are stable, this study could help improve post-transplant care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You received a heart transplant at St. Paul's Hospital.
- You are within the first year after your transplant.
- You are being followed at the Post-Transplant Clinic in Vancouver, BC.
- You are clinically stable during routine monitoring visits.
- You have not had certain high-risk factors like a positive crossmatch or multi-organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses tiny particles called extracellular vesicles (which cells release) to check for signs of organ rejection after a heart transplant, aiming for a safer and less invasive alternative to biopsies.
This study uses advanced heart imaging and blood tests to detect a type of rejection that can happen after a heart transplant. It may help doctors diagnose antibody-mediated rejection earlier and more accurately.
This study checks whether a special blood test can help detect heart transplant rejection or problems by comparing it to biopsy results. It may help your care team monitor your transplant with less guesswork.
This trial tests if a special MRI can detect early signs of heart rejection in children and young adults who have had a heart transplant. If successful, it might reduce the need for invasive biopsies.
This study tests a new approach to managing anti-rejection medicines after a heart transplant. It uses special blood tests to see if your immune system is calm, so doctors can safely reduce the medicines and lower side effects.
This trial is studying whether a blood test that measures small molecules called microRNAs can help doctors personalize the medicines used to prevent rejection after a heart transplant. If you qualify, you would help researchers learn how to better match immunosuppression to each patient's needs.
Hear when a new Heart Transplant Recipient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.